OncoVEX(mGM-CSF)expands tumor antigen-specific CD8+ T-cell response in preclinical models

BACKGROUND: Checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) have demonstrated clinical efficacy in advanced melanoma, but only a subset of patients with inflamed tumors are responsi...

Descripción completa

Detalles Bibliográficos
Autores principales: Estrada, Juan, Zhan, Jinghui, Mitchell, Petia, Werner, Jonathan, Beltran, Pedro J, DeVoss, Jason, Qing, Jing, Cooke, Keegan S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173969/
https://www.ncbi.nlm.nih.gov/pubmed/37164449
http://dx.doi.org/10.1136/jitc-2022-006374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173969/
https://www.ncbi.nlm.nih.gov/pubmed/37164449
http://dx.doi.org/10.1136/jitc-2022-006374

Ejemplares similares